ethyl-(1-methylene-3-phenyl-prop-2-ynyl)-ether | 164469-92-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl-(1-methylene-3-phenyl-prop-2-ynyl)-ether
• 英文别名: Aethyl-(1-methylen-3-phenyl-prop-2-inyl)-aether；3-Aethoxy-1-phenyl-buten-(3)-in-(1)；3-Ethoxybut-3-en-1-ynylbenzene
• CAS: 164469-92-5
• 化学式: C₁₂H₁₂O
• 分子量: 172.227
• InChiKey: GYDYBZVLADGUIZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  ethyl-(1-methylene-3-phenyl-prop-2-ynyl)-ether 在 乙醇 、 镍 作用下， 生成 (3-ethoxybutyl)benzene
  参考文献：
  名称：

  Golse, Annales de Chimie (Cachan, France), 1948, vol. <12> 3, p. 527,554

  摘要：

  DOI：
• 作为产物：
  描述：

  乙基-(1-溴甲基-3-苯基-丙-2-炔基)-醚 在 甲醇 、 sodium methylate 作用下， 生成 ethyl-(1-methylene-3-phenyl-prop-2-ynyl)-ether
  参考文献：
  名称：

  Golse, Annales de Chimie (Cachan, France), 1948, vol. <12> 3, p. 527,554

  摘要：

  DOI：

文献信息

• Methylenations of heteroatom-substituted carbonyls with dimethyl titanocene
  作者：Nicos A. Petasis、Shao-Po Lu

  DOI：10.1016/0040-4039(95)00320-c

  日期：1995.4

  Reaction of dimethyl titanocene with a variety of heteroatom-substituted carbonyl compounds, including: silylesters, anhydrides, carbonates, amides, imides, thioesters, selenoesters and acyl silanes gives the corresponding heteroatom-substituted alkenes.

  二甲基钛茂与多种杂原子取代的羰基化合物反应，包括：甲硅烷基酯，酸酐，碳酸盐，酰胺，酰亚胺，硫代酸酯，硒酸酯和酰基硅烷，得到相应的杂原子取代的烯烃。
• Trostyanskaya; Shvetsov; Efimova, Russian Journal of Organic Chemistry, 1996, vol. 32, # 7, p. 946 - 950
  作者：Trostyanskaya、Shvetsov、Efimova、Kazankova、Beletskaya

  DOI：——

  日期：——
• Golse, Annales de Chimie (Cachan, France), 1948, vol. <12> 3, p. 527,554
  作者：Golse

  DOI：——

  日期：——
• Comorbidity and other factors associated with modality selection in incident dialysis patients: The CHOICE study
  作者：Dana C. Miskulin、Klemens B. Meyer、Nicolaos V. Athienites、Alice A. Martin、Norma Terrin、Jane V. Marsh、Nancy E. Fink、Josef Coresh、Neil R. Powe、Mike J. Klag、Andrew S. Levey

  DOI：10.1053/ajkd.2002.30552

  日期：2002.2

  Case-mix factors influence both the selection of dialysis modality and outcomes In end-stage renal disease (ESRD). A detailed characterization of the case-mix differences between peritoneal dialysis (PD) and hemodialysis (HD) patients at the onset of dialysis therapy has not been performed, despite the Importance of accounting for baseline differences in future comparisons of outcomes across modality groups. We compared baseline characteristics of 279 PD and 759 HD patients enrolled in the Choices for Healthy Outcomes In Caring for End-Stage Renal Disease (CHOICE) Cohort Study, a prospective study of Incident dialysis patients. Comorbidity was assessed using the Index of Coexistent Diseases (ICED), consisting of a medical record review of 19 medical conditions and an observer-based assessment of 11 physical functions. ICED scores range from 0 to 3, with higher levels reflecting more severe comorbidity. Comorbidity was less severe in PD patients than In HD patients: the proportions of patients with ICED 0-1, ICED 2, and ICED 3 were 52%, 26%, and 22%, respectively, among the PD patients and 30%, 39%, and 31%, respectively, among the HD patients (P < 0.001). After controlling for all other factors, the differences In comorbidity remained significant. As compared with patients with ICED 0-1, the odds of being treated with PD for patients with ICED 2 and ICED 3 were less (odds ratio [OR] and 95% confidence Intervals) 0.31 (0.17 to 0.56) and 0.50 (0.28 to 0.90), respectively. The number and severity of comorbid conditions at the onset of ESRD is significantly lower In patients choosing PD, independent of other factors influencing modality selection. The increased survival of PD patients reported in recent studies may simply reflect the self- or physician-directed selection of healthier patients to PD. Adjustment for case-mix differences In patients treated with PD versus HD is essential to the assessment of the independent effect of the dialysis modality on outcomes. (C) 2002 by the National Kidney Foundation, Inc.